Emcure Pharmaceuticals reported consolidated revenue from operations of Rs 9,204 crore for FY26, marking a 16.6 per cent year-on-year increase and crossing the US$1 billion revenue milestone for the first time.

The company posted EBITDA of Rs 1,789 crore, up 21.8 per cent YoY, with EBITDA margins improving to 19.4 per cent from 18.6 per cent in FY25. Reported profit after tax (PAT) rose 33.1 per cent YoY to Rs 941 crore, while adjusted PAT increased 40.9 per cent to Rs 1,008 crore.

For the fourth quarter ended March 31, 2026, Emcure reported revenue of Rs 2,470 crore, up 16.7 per cent YoY. Quarterly EBITDA grew 24.5 per cent to Rs 485 crore, while PAT rose 23.6 per cent to Rs 244 crore. Adjusted PAT for Q4 stood at Rs 279 crore, registering 36 per cent growth.

Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, said FY26 marked the first year of the company’s five-year strategic plan, with strong growth across domestic and international markets.

The domestic business recorded sales of Rs 4,027 crore in FY26, up 10 per cent YoY, supported by growth in cardiac, CNS and oncology segments. The company said it strengthened domestic operations through the minority stake buyout in Zuventus, leadership expansion, and partnerships with multinational companies.

International business revenue rose 22.2 per cent YoY to Rs 5,177 crore, driven by base business expansion and new product launches from the in-house portfolio. Europe emerged as the fastest-growing international market with 25.5 per cent annual growth, followed by Canada at 18.7 per cent and emerging markets at 21.8 per cent.

In Q4FY26, domestic sales grew 5.2 per cent to Rs 977 crore, while international sales surged 25.7 per cent to Rs 1,493 crore.

The company also highlighted strategic expansion initiatives during the year, including in-licensing deals, the Zuventus minority buyout, and bolt-on acquisitions in the UK and Canada. Emcure said its R&D pipeline in complex injectables and biosimilars remains a key growth driver for the future.